When uveal melanoma — a rare form of eye cancer — spreads to the liver, experience matters. That experience is built one patient at a time, with every procedure requiring precision and coordination among dozens of medical professionals.
As of July 2026, HonorHealth care teams have completed more than 50 HEPZATO® procedures, an important benchmark achieved by only a small number of programs nationwide. The treatment delivers high-dose chemotherapy directly to the liver, filtering it from the bloodstream before it returns to the rest of the body. Because of its complexity and strict FDA safety requirements, it’s offered at a limited number of medical centers across the country.
“I’m very proud of our HonorHealth HEPZATO team. Reaching 50 procedures is a significant milestone and a testament to the continued trust our patients place in us,” said Jason Low, MD, interventional radiologist at HonorHealth. “It’s such a pleasure to see physicians and staff from so many different specialties come together for every patient. Collaboration is what makes this program successful.”
“For patients with metastatic uveal melanoma, HEPZATO is one of the most effective treatment options available. We are so honored to have Dr. Low and his world-class team here at HonorHealth, offering this procedure to our patients,” said Justin Moser, MD, medical oncologist at HonorHealth.
Every procedure represents another patient who can receive this advanced treatment close to home, reinforcing HonorHealth’s commitment to expanding access and leading innovative cancer care across Arizona.